{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:05:19Z","timestamp":1780416319690,"version":"3.54.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:00:00Z","timestamp":1554249600000},"content-version":"am","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.drugalcdep.2017.11.031","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T12:58:32Z","timestamp":1519217912000},"page":"411-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs"],"prefix":"10.1016","volume":"185","author":[{"given":"Bruce R.","family":"Schackman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gutkind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake R.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared A.","family":"Leff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Czarina N.","family":"Behrends","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Delucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"McKnight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Perlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen L.","family":"Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P.","family":"Linas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.drugalcdep.2017.11.031_bib0005","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1128\/JCM.36.4.862-865.1998","article-title":"Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory","volume":"36","author":"Albadalejo","year":"1998","journal-title":"J. Clin. Microbiol."},{"issue":"4","key":"10.1016\/j.drugalcdep.2017.11.031_bib0010","first-page":"120","article-title":"Public policy statement on hepatitis C: supplemental information for physicians","volume":"23","author":"American Society of Addiction Medicine","year":"2004","journal-title":"J. Addict. Disord."},{"issue":"3","key":"10.1016\/j.drugalcdep.2017.11.031_bib0015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","article-title":"Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States","volume":"163","author":"Barua","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2017.11.031_bib0020","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MLR.0b013e31815c31a7","article-title":"What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?","volume":"46","author":"Braithwaite","year":"2008","journal-title":"Med. Care"},{"key":"10.1016\/j.drugalcdep.2017.11.031_bib0025","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","article-title":"Model parameter estimation and uncertainty: a report of the ISPOR-SMDM modeling good research practices task force-6","volume":"15","author":"Briggs","year":"2012","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.drugalcdep.2017.11.031_bib0030","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2009.31","article-title":"Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study","volume":"104","author":"Bruno","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.drugalcdep.2017.11.031_bib0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jsat.2016.12.014","article-title":"Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program","volume":"75","author":"Butner","year":"2017","journal-title":"J. Subst. Abuse Treat."},{"issue":"3","key":"10.1016\/j.drugalcdep.2017.11.031_bib0040","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1572-0241.2003.07332.x","article-title":"Health-state utilities and quality of life in hepatitis C patients","volume":"98","author":"Chong","year":"2003","journal-title":"Am. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.drugalcdep.2017.11.031_bib0045","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1365-2893.2001.00280.x","article-title":"Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature","volume":"8","author":"Colin","year":"2001","journal-title":"J. Viral Hepat."},{"issue":"5","key":"10.1016\/j.drugalcdep.2017.11.031_bib0050","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/M13-1133","article-title":"Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2013","volume":"160","author":"Denniston","year":"2014","journal-title":"Ann. Intern. Med."},{"issue":"9","key":"10.1016\/j.drugalcdep.2017.11.031_bib0055","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir\u2013Grazoprevir to treat hepatitis c virus infection in persons receiving opioid agonist therapy: a randomized trial","volume":"165","author":"Dore","year":"2016","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.drugalcdep.2017.11.031_bib0060","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/add.12863","article-title":"Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10","volume":"110","author":"Evans","year":"2015","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.drugalcdep.2017.11.031_bib0065","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/hec.903","article-title":"Cost-effectiveness acceptability curves\u2013facts, fallacies and frequently asked questions","volume":"13","author":"Fenwick","year":"2004","journal-title":"Health Econ."},{"issue":"4 Pt 1","key":"10.1016\/j.drugalcdep.2017.11.031_bib0070","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1053\/jhep.2001.27831","article-title":"Estimating progression to cirrhosis in chronic hepatitis C virus infection","volume":"34","author":"Freeman","year":"2001","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.drugalcdep.2017.11.031_bib0075","first-page":"1028","volume":"103","author":"Frimpong","year":"2013","journal-title":"Missed opportunities for hepatitis C testing in opioid treatment programs Am J Public Health"},{"issue":"1","key":"10.1016\/j.drugalcdep.2017.11.031_bib0080","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0168-8278(96)80183-8","article-title":"Clinical evaluation of a single reaction, diagnostic polymerase chain reaction assay for the detection of hepatitis C virus RNA","volume":"24","author":"Gerken","year":"1996","journal-title":"J. Hepat."},{"issue":"11","key":"10.1016\/j.drugalcdep.2017.11.031_bib0085","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/cid\/ciw579","article-title":"Efficacy and safety of Sofosbuvir\/Velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials","volume":"63","author":"Grebely","year":"2016","journal-title":"Clin. Infect Dis."},{"issue":"9","key":"10.1016\/j.drugalcdep.2017.11.031_bib0090","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/gut.2005.064774","article-title":"Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C","volume":"55","author":"Grieve","year":"2006","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.drugalcdep.2017.11.031_bib0095","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/infdis\/jir196","article-title":"A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs","volume":"204","author":"Hagan","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2017.11.031_bib0100","first-page":"1","article-title":"Cost effectiveness and cost containment in the era of interferon-free therapies to treat hepatitis c virus genotype 1","author":"Linas","year":"2016","journal-title":"Open Forum Infect. Dis."},{"issue":"1","key":"10.1016\/j.drugalcdep.2017.11.031_bib0105","doi-asserted-by":"crossref","first-page":"ofw266","DOI":"10.1093\/ofid\/ofw266","article-title":"Cost effectiveness and cost containment in the era of interferon-free therapies to treat hepatitis C virus genotype 1","volume":"4","author":"Linas","year":"2017","journal-title":"Open Forum Infect. Dis."},{"issue":"62","key":"10.1016\/j.drugalcdep.2017.11.031_bib0110","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/cid\/ciw111","article-title":"Rising mortality associated with hepatitis c virus in the United States, 2003\u20132013","volume":"10","author":"Ly","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.drugalcdep.2017.11.031_bib0115","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.2105\/AJPH.2013.301458","article-title":"A randomized trial of a hepatitis care coordination model in methadone maintenance treatment","volume":"103","author":"Masson","year":"2013","journal-title":"Am. J. Public Health"},{"issue":"1","key":"10.1016\/j.drugalcdep.2017.11.031_bib0120","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.drugalcdep.2017.11.031_bib0125","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies","volume":"13","author":"Micallef","year":"2006","journal-title":"J. Viral Hepat."},{"issue":"1","key":"10.1016\/j.drugalcdep.2017.11.031_bib0130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jviromet.2008.12.009","article-title":"A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen","volume":"157","author":"Morota","year":"2009","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.drugalcdep.2017.11.031_bib0135","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness \u2013 the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2017.11.031_bib0140","series-title":"Cost-Effectiveness in Health and Medicine","author":"Neumann","year":"2017"},{"issue":"12","key":"10.1016\/j.drugalcdep.2017.11.031_bib0145","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1111\/add.12682","article-title":"The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users","volume":"109","author":"Nolan","year":"2014","journal-title":"Addiction"},{"issue":"342","key":"10.1016\/j.drugalcdep.2017.11.031_bib0150","article-title":"Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting","volume":"11","author":"Petrou","year":"2011","journal-title":"BMJ"},{"issue":"9055","key":"10.1016\/j.drugalcdep.2017.11.031_bib0155","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet."},{"key":"10.1016\/j.drugalcdep.2017.11.031_bib0160","series-title":"Heptatis C: The State of Medicaid Access Preliminary Findings National Summary Report","author":"Roundtable","year":"2016"},{"issue":"1","key":"10.1016\/j.drugalcdep.2017.11.031_bib0165","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0272989X0202200103","article-title":"Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV\/AIDS","volume":"22","author":"Schackman","year":"2002","journal-title":"Med. Decis. Making"},{"key":"10.1016\/j.drugalcdep.2017.11.031_bib0170","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/add.12754","article-title":"Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs","volume":"110","author":"Schackman","year":"2015","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.drugalcdep.2017.11.031_bib0175","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/0272989X07311753","article-title":"Quality-of-life tradeoffs for hepatitis C treatment: do patients and providers agree?","volume":"28","author":"Schackman","year":"2008","journal-title":"Med. Decis. Making"},{"issue":"16","key":"10.1016\/j.drugalcdep.2017.11.031_bib0180","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1097\/QAD.0b013e328330ed24","article-title":"Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus","volume":"23","author":"Schnuriger","year":"2009","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.drugalcdep.2017.11.031_bib0185","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/cid\/cir499","article-title":"Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites","volume":"53","author":"Smith","year":"2011","journal-title":"Clin. Infect Dis."},{"issue":"9","key":"10.1016\/j.drugalcdep.2017.11.031_bib0190","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1086\/592171","article-title":"Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe","volume":"198","author":"Soriano","year":"2008","journal-title":"J. Infect Dis."},{"issue":"31","key":"10.1016\/j.drugalcdep.2017.11.031_bib0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta6310","article-title":"Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice","volume":"6","author":"Stein","year":"2002","journal-title":"Health Technol. Assess."},{"issue":"6","key":"10.1016\/j.drugalcdep.2017.11.031_bib0200","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/apt.12880","article-title":"Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens","volume":"40","author":"Stepanova","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.drugalcdep.2017.11.031_bib0205","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology"},{"issue":"15","key":"10.1016\/j.drugalcdep.2017.11.031_bib0210","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1097\/QAD.0b013e32830e6d51","article-title":"Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis","volume":"22","author":"Thein","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.drugalcdep.2017.11.031_bib0215","series-title":"Hepatitis C: drug therapy","author":"Truven Health Analytics","year":"2016"},{"issue":"2","key":"10.1016\/j.drugalcdep.2017.11.031_bib0220","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1586\/14737167.5.2.153","article-title":"Practical approach for using Medicare data to estimate costs for cost\u2013effectiveness analysis","volume":"5","author":"Tumeh","year":"2005","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"10.1016\/j.drugalcdep.2017.11.031_bib0225","series-title":"Civilian labor force participation rate by age, gender, race and ethnicity","author":"U.S. Bureau of Labor Statistics","year":"2015"},{"key":"10.1016\/j.drugalcdep.2017.11.031_bib0230","series-title":"Occupational employment statistics","author":"U.S. Bureau of Labor Statistics","year":"2015"},{"issue":"24","key":"10.1016\/j.drugalcdep.2017.11.031_bib0235","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"Van der Meer","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2017.11.031_bib0240","series-title":"The Federal Supply Schedule","author":"Veterans Affairs Office of Acquisition and Logistics (OAL)","year":"2016"},{"issue":"4","key":"10.1016\/j.drugalcdep.2017.11.031_bib0245","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/add.13219","article-title":"Measuring benefits of opioid misuse treatment for economic evaluation: health-related quality of life of opioid-dependent individuals and their spouses as assessed by a sample of the US population","volume":"111","author":"Wittenberg","year":"2016","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.drugalcdep.2017.11.031_bib0250","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jval.2016.09.2404","article-title":"Joint utility estimators in substance use disorders","volume":"20","author":"Wittenberg","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.drugalcdep.2017.11.031_bib0255","series-title":"Updated National Viral Hepatitis Action Plan 2017\u20132020. Health and Human Services","author":"Wolitski","year":"2016"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871618300255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871618300255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T08:56:01Z","timestamp":1759827361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871618300255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":51,"alternative-id":["S0376871618300255"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.11.031","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.11.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}